Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.68 |
| ▸ | STS | P08842 | 10/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 2/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
| ▸ | SHBG | P04278 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130255 | 0.86 | CA1 (0.74) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL10481850 | 0.85 | CA1 (0.73) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL15307861 | 0.85 | STS (0.74) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL15307860 | 0.85 | STS (0.74) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL13216961 | 0.85 | STS (0.74) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL10080238 | 0.85 | STS (0.74) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL15625964 | 0.84 | CA1 (0.72) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL31321075 | 0.83 | CA1 (0.70) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL12966629 | 0.83 | STS (0.71) | CA1CA2CA9CA5AHSD17B1 | |
| SCHEMBL15609121 | 0.83 | STS (0.71) | CA1CA2CA9CA5AHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1916254-A3 | 17alpha-alkyl-17beta-oxy-estratriene and intermediates for its production, use of 17alpha-alkyl-17beta-oxy-estratriene for manufacturing medicine and pharmaceutical preparations | Bayer Intellectual Property GmbH (DE) | 2012-11-14 | — | — | EP | disclosed |
| US-7538100-B2 | 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1916254-A2 | 17alpha-alkyl-17beta-oxy-estratriene and intermediates for its production, use of 17alpha-alkyl-17beta-oxy-estratriene for manufacturing medicine and pharmaceutical preparations | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-30 | — | — | EP | disclosed |
| JP-2006306896-A | 17alpha-ALKYL-17beta-OXY-ESTRATRIENES, INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND USE OF THE 17alpha-ALKYL-17beta-OXY-ESTRATRIENES FOR PRODUCING PHARMACEUTICAL AGENT AND PHARMACEUTICAL PREPARATION | SCHERING AG | 2006-11-09 | — | — | JP | disclosed |
| US-7018994-B2 | 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17α-ALKYL-17β-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS | SCHERING AG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-12 | — | — | US | disclosed |
| JP-2005120110-A | 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE FOR PRODUCTION THEREOF, AND USE OF 17α-ALKYL-17β-OXY-ESTRATRIENE FOR PRODUCTION OF MEDICAMENT AND PHARMACEUTICAL PREPARATION | SCHERING AG | 2005-05-12 | — | — | JP | disclosed |
| US-20030191099-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | SCHERING AG (DE) | 2003-10-09 | — | — | US | disclosed |
| WO-2003045972-A1 | 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17α-ALKYL-17β-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | CA1 2766/4885CA2 3504/4885CA9 2973/4885 |
| US-20030191099-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | CA1 2761/4885CA2 3468/4885CA9 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.